As of 2025-09-13, the Relative Valuation of Apellis Pharmaceuticals Inc (APLS) is (23.94) USD. This relative valuation is based on P/E multiples. With the latest stock price at 24.85 USD, the upside of Apellis Pharmaceuticals Inc based on Relative Valuation is -196.3%.
The range of the Relative Valuation is (19.22) - (27.35) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 15.1x | 13.3x |
| Forward P/E multiples | 7.8x - 16.6x | 13.2x |
| Fair Price | (19.22) - (27.35) | (23.94) |
| Upside | -177.4% - -210.1% | -196.3% |
| Date | P/E |
| 2025-09-11 | -14.06 |
| 2025-09-10 | -14.41 |
| 2025-09-09 | -14.86 |
| 2025-09-08 | -14.89 |
| 2025-09-05 | -15.57 |
| 2025-09-04 | -15.86 |
| 2025-09-03 | -15.39 |
| 2025-09-02 | -15.59 |
| 2025-08-29 | -15.26 |
| 2025-08-28 | -15.53 |
| 2025-08-27 | -15.62 |
| 2025-08-26 | -15.46 |
| 2025-08-25 | -15.23 |
| 2025-08-22 | -15.48 |
| 2025-08-21 | -15.29 |
| 2025-08-20 | -14.71 |
| 2025-08-19 | -14.77 |
| 2025-08-18 | -15.14 |
| 2025-08-15 | -15.36 |
| 2025-08-14 | -15.29 |
| 2025-08-13 | -14.71 |
| 2025-08-12 | -13.23 |
| 2025-08-11 | -13.20 |
| 2025-08-08 | -13.49 |
| 2025-08-07 | -13.47 |
| 2025-08-06 | -13.13 |
| 2025-08-05 | -13.39 |
| 2025-08-04 | -13.43 |
| 2025-08-01 | -12.70 |
| 2025-07-31 | -12.36 |
| 2025-07-30 | -10.52 |
| 2025-07-29 | -10.49 |
| 2025-07-28 | -10.38 |
| 2025-07-25 | -10.84 |
| 2025-07-24 | -11.12 |
| 2025-07-23 | -11.01 |
| 2025-07-22 | -11.01 |
| 2025-07-21 | -10.67 |
| 2025-07-18 | -10.78 |
| 2025-07-17 | -11.09 |
| 2025-07-16 | -10.93 |
| 2025-07-15 | -10.71 |
| 2025-07-14 | -11.02 |
| 2025-07-11 | -10.76 |
| 2025-07-10 | -10.81 |
| 2025-07-09 | -10.63 |
| 2025-07-08 | -9.90 |
| 2025-07-07 | -9.64 |
| 2025-07-03 | -10.11 |
| 2025-07-02 | -9.86 |